Abstract
In the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial conducted by White et al. (March 29 issue from NEJM), all-cause mortality and cardiovascular mortality are found to be higher among patients randomly assigned to febuxostat compared to allopurinol, but significant flaws are a clear lack of treat to target strategy with more powered treatment in the febuxostat arm, dysbalance with cardiovascular risk factors selectively in again the febuxostat arm, and discontinuation of the trial regimen in over 50% of patients with discontinuation of follow-up in about 45%. With these flaws, conclusions such as febuxostat-associated higher mortality are potentially if not probably incorrect, and thus febuxostat to be used not as first-line therapy may well be an invalid consequence? The paper here describes potential lessons to be taken.
This is a preview of subscription content, log in via an institution to check access.
References
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, CARES Investigators (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200–1210
Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R (2018) New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated FDE public safety alert. A&R 70:1702–1709. https://doi.org/10.1002/art.40583
Yeum K-J, Russell RM, Krinsky NI, Aldini G (2004) Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 430:97–103
Odden MC, Amadu A-R, Smit E, Lo L, Peralta CA (2014) Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis 64:550–557
Kang E, Hwang S-S, Kim DK, Oh KH, Joo KW, Kim YS, Lee H (2017) Sex-specific relationship of serum uric acid with all-cause mortality in adults with normal kidney function: an observational study. J Rheumatol 44:380–387
Tseng WC, Chen YT, Ou SM, Shih CJ, Tarng DC, for the Taiwan Geriatric Kidney Disease (TGKD) Research Group, for the Taiwan Geriatric Kidney Disease (TGKD) Research Group, Tarng DC, Tseng WC, Ou SM, Yang CY, Lin YP, Chuang YF, Chen LK, Wang KY, Chen YH, Tsai MT, Shih CJ, Chen YT, Lin YS, Hung SC, Kuo KL, Hung TP, Hu FH, Chen NJ, Chen YC, Lin CH, Tsai TH, Hsieh SL, Wei YH, Hsu CC, Liu JS, Chang YK, Chiang MH (2018) U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: the role of malnourishment. J Am Heart Assoc 10:7. https://doi.org/10.1161/JAHA.117.007523.
Jansen TL, Richette P, Perez-Ruiz F, Tausche AK, Guerne PA, Punzi L, Leeb B, Barskova V, Uhlig T, Pimentão J, Zimmermann-Górska I, Pascual E, Bardin T, Doherty M (2010) International position paper on febuxostat. Clin Rheumatol 29:835–840. https://doi.org/10.1007/s10067-010-1457-8
Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131
Solomon DH, Glynn RJ, MacFadyen JG et al (2018) Relationship of interleukin-1beta blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Int Med 169:535–542
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42. https://doi.org/10.1136/annrheumdis2016U209707.
Jansen TL, Perez-Ruiz F, Tausche A-K, Richette P (2018) International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol 37:3159–3165. https://doi.org/10.1007/s10067-018-4306-9
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jansen, T.L.T.A., Janssen, M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clin Rheumatol 38, 263–265 (2019). https://doi.org/10.1007/s10067-018-4396-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4396-4